Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: Implications for alcohol reward and seeking

Journal of Neuroscience

Volumn 31, Issue 27, 2011, Pages 9885-9894

  Barak, Segev ^a   Carnicella, Sebastien ^a,b   Yowell, Quinn V ^a   Ron, Dorit ^a  

^a UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

^b GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ALLOSTASIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG TARGETING; IN VIVO STUDY; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; VENTRAL TEGMENTUM;

ALCOHOL DRINKING; ALCOHOLS; ALLOSTASIS; ANIMALS; CHOICE BEHAVIOR; CONDITIONING, OPERANT; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; LIMBIC SYSTEM; MALE; MICRODIALYSIS; MODELS, BIOLOGICAL; MOTOR ACTIVITY; RATS; RATS, LONG-EVANS; REWARD; SELF ADMINISTRATION; STATISTICS, NONPARAMETRIC;

EID: 79960048732     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1750-11.2011     Document Type: Article

References (75)

1. Ahmed SH, Koob GF (1998) Transition from moderate to excessive drug intake: change in hedonic set point. Science 282:298-300.
2. Ahmed SH, Koob GF (2005) Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. Psychopharmacology (Berl) 180:473-490.
3. Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394.
4. Bailey CP, O'Callaghan MJ, Croft AP, Manley SJ, Little HJ (2001) Alterations in mesolimbic dopamine function during the abstinence period following chronic ethanol consumption. Neuropharmacology 41:989-999.
5. Bardo MT, Bevins RA (2000) Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl) 153:31-43.
6. Barrett AC, Miller JR, Dohrmann JM, Caine SB (2004) Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antago-nists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 47 [Suppl 1]:256-273.
7. Bespalov MM, Saarma M (2007) GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 28:68 -74.
8. Carnicella S, Ron D (2009) GDNF-a potential target to treat addiction. Pharmacol Ther 122:9-18.
9. Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D (2008) GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci U S A 105:8114-8119.
10. Carnicella S, Amamoto R, Ron D (2009a) Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. Alcohol 43:35-43.
11. Carnicella S, Ahmadiantehrani S, Janak PH, Ron D (2009b) GDNF is an endogenous negative regulator of ethanol-mediated reward and of ethanol consumption after a period of abstinence. Alcohol Clin Exp Res 33:1012-1024.
12. Carnicella S, Ahmadiantehrani S, He DY, Nielsen CK, Bartlett SE, Janak PH, Ron D (2009c) Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor. Biol Psychiatry 66:146-153.
13. Carnicella S, Yowell QV, Ron D (2011) Regulation of operant oral ethanol self-administration: a dose-response curve study in rats. Alcohol Clin Exp Res 35:116-125.
14. Cohen C, Perrault G, Sanger DJ (1997) Evidence for the involvement of dopamine receptors in ethanol-induced hyperactivity in mice. Neuropharmacology 36:1099-1108.
15. Cunningham CL, Gremel CM, Groblewski PA (2006) Drug-induced conditioned place preference and aversion in mice. Nat Protoc 1:1662-1670.
16. Daniel M, Martin AD, Carter J (1992) Opiate receptor blockade by naltrexone and mood state after acute physical activity. Br J Sports Med 26:111-115.
17. Darden JH, Hunt WA (1977) Reduction of striatal dopamine release during an ethanol withdrawal syndrome. J Neurochem 29:1143-1145.
18. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL (2005) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25:1889-1893.
19. Diana M, Pistis M, Carboni S, Gessa GL, Rossetti ZL (1993) Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc Natl Acad Sci U S A 90:7966-7969.
20. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278.
21. Gerlai R, McNamara A, Choi-Lundberg DL, Armanini M, Ross J, Powell- Braxton L, Phillips HS (2001) Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. Eur J Neurosci 14:1153-1163.
22. Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L (2010) Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev 35:157-171.
23. Gibb SL, Jeanblanc J, Barak S, Yowell QV, Yaka R, Ron D (2011) Lyn kinase regulates mesolimbic dopamine release: implication for alcohol reward. J Neurosci 31:2180-2187.
24. Gil E, Colado I, Lopez F, Fernandez-Briera A, Fernandez-Lopez A, Calvo P (1992) Effects of chronic treatment with ethanol and withdrawal of ethanol on levels of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid in the striatum of the rat. Influence of benzodiazepines, barbiturate and somatostatin. Neuropharmacology 31:1151-1156.
25. Ginsburg BC, Martinez G, Friesenhahn G, Javors M, Lamb RJ (2008) Acutetolerance to rate-decreasing effects of single doses of ethanol. Physiol Behav 94:374-383.
26. Gonzales RA, Job MO, Doyon WM (2004) The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol Ther 103:121-146.
27. Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW (2007) Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 10:1029-1037.
28. Gremel CM, Cunningham CL (2008) Roles of the nucleus accumbens and amygdala in the acquisition and expression of ethanol-conditioned behavior in mice. J Neurosci 28:1076-1084.
29. Gremel CM, Cunningham CL (2009) Involvement of amygdala dopamine and nucleus accumbens NMDA receptors in ethanol-seeking behavior in mice. Neuropsychopharmacology 34:1443-1453.
30. Hebert MA, Van Horne CG, Hoffer BJ, Gerhardt GA (1996) Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J Pharmacol Exp Ther 279:1181-1190.
31. Hudson J, Granholm AC, Gerhardt GA, Henry MA, Hoffman A, Biddle P, Leela NS, Mackerlova L, Lile JD, Collins F (1995) Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432.
32. Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29:565-598.
33. Ikemoto S (2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 56:27-78.
34. Kalivas PW, Stewart J (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 16:223-244.
35. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF (2006) Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 26:5894-5900.
36. Keppel G (1991) Design and analysis: a researcher's handbook, Ed 3. Upper Saddle River, NJ: Prentice Hall.
37. Kim SW (1998) Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 59:159-164.
38. Koob GF (1996) Drug addiction: the yin and yang of hedonic homeostasis. Neuron 16:893-896.
39. Koob GF (2003) Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 27:232-243.
40. Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52-58.
41. Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24:97-129.
42. Lenoir M, Keiflin R (2006) Heroin addiction: anticipating the reward of heroin or the agony of withdrawal? J Neurosci 26:9080-9081.
43. Lewis MJ, June HL (1990) Neurobehavioral studies of ethanol reward and activation. Alcohol 7:213-219.
44. Leyton M (2007) Conditioned and sensitized responses to stimulant drugs in humans. Prog Neuropsychopharmacol Biol Psychiatry 31:1601-1613.
45. Li SM, Newman AH, Katz JL (2005) Place conditioning and locomotor effects of N-substituted, 4,4-difluorobenztropine analogs in rats. J Pharmacol Exp Ther 313:1223-1230.
46. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
47. Lu L, Wang X, Wu P, Xu C, Zhao M, Morales M, Harvey BK, Hoffer BJ, Shaham Y (2009) Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving. Biol Psychiatry 66:137-145.
48. Lynch WJ, Carroll ME (2001) Regulation of drug intake. Exp Clin Psychopharmacol 9:131-143.
49. Maisonneuve IM, Glick SD (1999) Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine. Eur J Pharmacol 383:15-21.
50. McBride WJ, Murphy JM, Ikemoto S (1999) Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial placeconditioning studies. Behav Brain Res 101:129-152.
51. Mello NK, Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14:375-424.
52. Meyer PJ, Meshul CK, Phillips TJ (2009) Ethanol- and cocaine-induced locomotion are genetically related to increases in accumbal dopamine. Genes Brain Behav 8:346-355.
53. Murphy MR, Checkley SA, Seckl JR, Lightman SL (1990) Naloxone inhibits oxytocin release at orgasm in man. J Clin Endocrinol Metab 71:1056-1058.
54. Nurmi M, Kiianmaa K, Sinclair JD (1994) Brain ethanol in AA, ANA, and Wistar rats monitored with one-minute microdialysis. Alcohol 11:315-321.
55. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gó mez-Díaz R, Ló pez-Barneo J (2008) Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11:755-761.
56. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, Ed 4. San Diego: Academic.
57. Piazza PV, Deroche-Gamonent V, Rouge-Pont F, Le Moal M (2000) Verticalshifts in self-administration dose-response functions predict a drugvulnerable phenotype predisposed to addiction. J Neurosci 20:4226-4232.
58. Pierce RC, KumaresanV (2006) The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30:215-238.
59. Raje S, Cornish J, Newman AH, Cao J, Katz JL, Eddington ND (2005) Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling. Pharm Res 22:603-612.
60. Rossetti ZL, Melis F, Carboni S, Diana M, Gessa GL (1992) Alcohol withdrawal in rats is associated with a marked fall in extraneuronal dopamine. Alcohol Clin Exp Res 16:529-532.
61. Shen RY (2003) Ethanol withdrawal reduces the number of spontaneously active ventral tegmental area dopamine neurons in conscious animals. J Pharmacol Exp Ther 307:566-572.
62. Shen RY, Choong KC, Thompson AC (2007) Long-term reduction in ventral tegmental area dopamine neuron population activity following repeated stimulant or ethanol treatment. Biol Psychiatry 61:93-100.
63. Simms JA, Steensland P, Medina B, Abernathy KE, Chandler LJ, Wise R, Bartlett SE (2008) Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin Exp Res 32:1816-1823.
64. Simms JA, Bito-Onon JJ, Chatterjee S, Bartlett SE (2010) Long-Evans rats acquire operant self-administration of 20% ethanol without sucrose fading. Neuropsychopharmacology 35:1453-1463.
65. Smith JE, Co C, McIntosh S, Cunningham CC (2008) Chronic binge-like moderate ethanol drinking in rats results in widespread decreases in brain serotonin, dopamine, and norepinephrine turnover rates reversed by ethanol intake. J Neurochem 105:2134-2155.
66. Tanda G, Newman AH, Ebbs AL, Tronci V, Green JL, Tallarida RJ, Katz JL (2009) Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther 330:802-809.
67. Tzschentke TM (2007) Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12:227-462.
68. Velázquez-Sánchez C, Ferragud A, Hernández-Rabaza V, Nácher A, Merino V, Cardá M, Murga J, Canales JJ (2009) The dopamine uptake inhibitor 3 alpha-[bis(4-fluorophenyl)metoxy]-tropane reduces cocaine-induced early-gene expression, locomotor activity, and conditioned reward. Neuropsychopharmacology 34:2497-2507.
69. Velázquez-Sánchez C, Ferragud A, Murga J, Cardá M, Canales JJ (2010) The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaineinduced reward, locomotor stimulation and sensitization. Eur Neuropsychopharmacol 20:501-508.
70. Wang J, Carnicella S, Ahmadiantehrani S, He DY, Barak S, Kharazia V, Ben Hamida S, Zapata A, Shippenberg TS, Ron D (2010) Nucleus accumbensderived glial cell line-derived neurotrophic factor is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. J Neurosci 30:14502-14512.
71. Weiss F, Parsons LH, Schulteis G, Hyytiä P, Lorang MT, Bloom FE, Koob GF (1996) Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J Neurosci 16:3474-3485.
72. Wise RA (1973) Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacologia 29:203-210.
73. Wise RA (1987) The role of reward pathways in the development of drug dependence. Pharmacol Ther 35:227-263.
74. Yeomans MR, Gray RW (2002) Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 26:713-728.
75. Zapata A, Shippenberg TS (2005) Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels. Neuropharmacology 48:43-50.